Abstracts tagged "juvenile idiopathic arthritis (JIA) and malignancy"

Abstract Number: 2982 • 2016 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitors and the Risk of Malignancy in the Treatment of Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², Lang Chen², Daniel Horton³, James D. Lewis⁴, Ronac Mamtani⁴, Melissa Mannion⁵, Kenneth G. Saag⁶, Jie Zhang⁷ and Jeffrey R. Curtis⁶, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The possible association between tumor necrosis factor inhibitors (TNFi) in the treatment of juvenile idiopathic arthritis (JIA) and an increased risk of malignancy remains…
Abstract Number: 955 • 2015 ACR/ARHP Annual Meeting
Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)
Omid Zahedi Niaki¹, Ann E. Clarke², Rosalind Ramsey-Goldman³, Rae S.M. Yeung⁴, Kristen Hayward⁵, Kiem Oen⁶, Ciarán M. Duffy⁷, Alan M. Rosenberg⁸, Kathleen O'Neil⁹, Emily von Scheven¹⁰, Laura Schanberg¹¹, Jeremy Labrecque¹², Jennifer LF Lee¹³ and Sasha Bernatsky¹⁴, ¹Medicine, McGill University, Montreal, QC, Canada, ²Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Pediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁵Pediatric Rheumatology, University of Washington & SCH, Seattle, WA, ⁶Department of Pediatrics and Child Health, University of Manitoba; Head, Section of Pediatric Rheumatology, Children’s Hospital, University of Manitoba, The Children`s Hospital Foundation of Manitoba, Winnipeg, MB, Canada, ⁷Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁸Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁹Pediatric Rheumatology, RIley Hospital for Children, Indianapolis, IN, ¹⁰Dept of Pediatric Rheumatology, Univ of California San Francisco, San Francisco, CA, ¹¹Pediatrics, Duke Medical Center, Durham, NC, ¹²Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ¹³Clinical Epidemiology Rheum, McGill UHC/RVH, Montreal, QC, Canada, ¹⁴Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada
Background/Purpose: Given suspected links between inflammation and malignancy, several groups have attempted to elucidate the baseline risk of cancer in various inflammatory or autoimmune conditions, including rheumatoid arthritis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].